Trials / Recruiting
RecruitingNCT06574698
Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma
Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma: A Prospective, Single-Arm Clinical Study
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 64 (estimated)
- Sponsor
- Guangzhou Women and Children's Medical Center · Academic / Other
- Sex
- All
- Age
- 1 Year – 21 Years
- Healthy volunteers
- Not accepted
Summary
To explore the efficacy of adding anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy for newly diagnosed high risk neuroblastoma patients. To investigate wether anding Naxitamab in the induction phase will improve the response rate at the end of induction therapy and further improve the overall survival rate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Addition of anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy | Addition of anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy |
Timeline
- Start date
- 2024-05-06
- Primary completion
- 2029-12-31
- Completion
- 2032-12-31
- First posted
- 2024-08-28
- Last updated
- 2024-08-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06574698. Inclusion in this directory is not an endorsement.